Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 7/20 | 0.71 |
| ▸ | THRA | P10827 | 6/20 | 0.71 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.55 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.55 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890901 | 0.94 | THRB (0.69) | THRBTHRAS1PR2S1PR1S1PR3 | |
| SCHEMBL21475283 | 0.85 | THRB (0.59) | THRBTHRAS1PR2S1PR1S1PR3 | |
| SCHEMBL15270918 | 0.84 | THRB (0.71) | THRBTHRAPLA2G4BPTPN11PTPN1 | |
| SCHEMBL12215167 | 0.84 | THRB (0.71) | THRBTHRAPLA2G4BPTPN11PTPN1 | |
| SCHEMBL10141534 | 0.84 | THRA (0.58) | THRBTHRAS1PR2S1PR1S1PR3 | |
| SCHEMBL4900725 | 0.83 | THRB (1.00) | THRBTHRAS1PR2S1PR1S1PR3 | |
| SCHEMBL3263906 | 0.82 | THRA (0.57) | THRBTHRAS1PR2S1PR1S1PR3 | |
| SCHEMBL4899221 | 0.81 | THRB (1.00) | THRBTHRAS1PR2S1PR1S1PR3 | |
| SCHEMBL2358713 | 0.81 | PLA2G2A (0.66) | THRBTHRAPLA2G4BPLA2G2A | |
| SCHEMBL12215169 | 0.81 | THRA (0.66) | THRBTHRAPLA2G4BPTPN11PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2008-01-31 | — | — | US | disclosed |
| EP-1729756-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094810-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | AR, NR5A1, CYP17A1 | THRB 792/4885THRA 559/4885S1PR2 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.